Added to YB: 2026-03-13
Pitch date: 2026-03-12
QURE [neutral]
uniQure N.V.
Author Info
Company Info
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States.
Market Cap
$1.1B
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-6.69
P/E
-5.28
EV/Sales
65.59
Sector
Biotechnology
Category
value
Followup on uniQure's AMT-130
QURE (update): AMT-130 gene therapy for Huntington's reduces mHTT protein production, lowering metabolic load on neurons' clearance systems (UPS/autophagy). Hypothesis: extended treatment may enable disease regression as aggregates clear over time. 3yr data showed Stroop test improvement vs baseline. 4yr results expected to trend better than consensus; if motor scores improve, stock could re-rate significantly regardless of US regulatory uncertainty.
Read full article (4 min)